Bristol-Myers Squibb (NYSE:BMY) Stock Holdings Decreased by Entropy Technologies LP

Entropy Technologies LP reduced its position in Bristol-Myers Squibb (NYSE:BMY) by 19.2% during the 3rd quarter, HoldingsChannel.com reports. The fund owned 110,022 shares of the biopharmaceutical company’s stock after selling 26,086 shares during the quarter. Bristol-Myers Squibb makes up about 0.6% of Entropy Technologies LP’s holdings, making the stock its 24th largest holding. Entropy Technologies LP’s holdings in Bristol-Myers Squibb were worth $5,693,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in BMY. Atomi Financial Group Inc. purchased a new position in shares of Bristol-Myers Squibb in the first quarter worth approximately $231,000. Avantax Advisory Services Inc. grew its position in Bristol-Myers Squibb by 3.5% during the first quarter. Avantax Advisory Services Inc. now owns 69,961 shares of the biopharmaceutical company’s stock valued at $3,794,000 after purchasing an additional 2,336 shares in the last quarter. Bleakley Financial Group LLC grew its position in Bristol-Myers Squibb by 14.4% during the first quarter. Bleakley Financial Group LLC now owns 63,318 shares of the biopharmaceutical company’s stock valued at $3,434,000 after purchasing an additional 7,994 shares in the last quarter. TD Asset Management Inc grew its position in Bristol-Myers Squibb by 2.7% during the first quarter. TD Asset Management Inc now owns 1,648,245 shares of the biopharmaceutical company’s stock valued at $89,384,000 after purchasing an additional 42,682 shares in the last quarter. Finally, Eagle Bay Advisors LLC grew its position in Bristol-Myers Squibb by 5.5% during the first quarter. Eagle Bay Advisors LLC now owns 8,170 shares of the biopharmaceutical company’s stock valued at $443,000 after purchasing an additional 425 shares in the last quarter. 76.41% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the stock. Sanford C. Bernstein assumed coverage on shares of Bristol-Myers Squibb in a research report on Thursday, October 17th. They set a “market perform” rating and a $56.00 price objective on the stock. Barclays boosted their target price on shares of Bristol-Myers Squibb from $42.00 to $43.00 and gave the stock an “underweight” rating in a research report on Monday, October 7th. Deutsche Bank Aktiengesellschaft decreased their target price on shares of Bristol-Myers Squibb from $53.00 to $45.00 and set a “hold” rating for the company in a research report on Tuesday, July 23rd. BMO Capital Markets boosted their target price on shares of Bristol-Myers Squibb from $53.00 to $57.00 and gave the stock a “market perform” rating in a research report on Friday, November 1st. Finally, UBS Group boosted their target price on shares of Bristol-Myers Squibb from $50.00 to $54.00 and gave the stock a “neutral” rating in a research report on Wednesday, October 9th. One analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Bristol-Myers Squibb has a consensus rating of “Hold” and an average target price of $53.00.

Insider Activity at Bristol-Myers Squibb

In related news, SVP Phil M. Holzer sold 700 shares of the stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total value of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares in the company, valued at $654,091.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. In other Bristol-Myers Squibb news, SVP Phil M. Holzer sold 700 shares of the firm’s stock in a transaction that occurred on Monday, November 4th. The shares were sold at an average price of $55.62, for a total transaction of $38,934.00. Following the sale, the senior vice president now directly owns 11,760 shares in the company, valued at approximately $654,091.20. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Samit Hirawat bought 1,830 shares of the company’s stock in a transaction on Friday, November 1st. The shares were bought at an average price of $54.67 per share, for a total transaction of $100,046.10. Following the completion of the acquisition, the executive vice president now directly owns 62,109 shares in the company, valued at approximately $3,395,499.03. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here. 0.09% of the stock is currently owned by corporate insiders.

Bristol-Myers Squibb Trading Up 10.5 %

Shares of Bristol-Myers Squibb stock opened at $59.82 on Tuesday. Bristol-Myers Squibb has a 52-week low of $39.35 and a 52-week high of $61.08. The company’s fifty day moving average price is $51.87 and its two-hundred day moving average price is $46.78. The company has a debt-to-equity ratio of 2.83, a current ratio of 1.24 and a quick ratio of 1.09. The firm has a market capitalization of $121.33 billion, a PE ratio of -16.66, a price-to-earnings-growth ratio of 20.09 and a beta of 0.44.

Bristol-Myers Squibb (NYSE:BMY) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported $1.80 EPS for the quarter, topping analysts’ consensus estimates of $1.49 by $0.31. Bristol-Myers Squibb had a negative net margin of 15.30% and a positive return on equity of 11.94%. The firm had revenue of $11.89 billion for the quarter, compared to analyst estimates of $11.26 billion. During the same quarter in the prior year, the firm earned $2.00 EPS. The company’s revenue was up 8.4% on a year-over-year basis. On average, analysts expect that Bristol-Myers Squibb will post 0.92 EPS for the current year.

Bristol-Myers Squibb Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Friday, November 1st. Investors of record on Friday, October 4th were given a $0.60 dividend. The ex-dividend date of this dividend was Friday, October 4th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 4.01%. Bristol-Myers Squibb’s dividend payout ratio is -66.85%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.